{"id":3968,"date":"2024-05-08T10:02:06","date_gmt":"2024-05-08T02:02:06","guid":{"rendered":"https:\/\/flcube.com\/?p=3968"},"modified":"2024-11-25T12:37:13","modified_gmt":"2024-11-25T04:37:13","slug":"chinas-sciwind-biosciences-partners-with-hk-inno-n-for-ecnoglutide-rights-in-south-korea","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=3968","title":{"rendered":"China\u2019s Sciwind Biosciences Partners with HK inno.N for Ecnoglutide Rights in South Korea"},"content":{"rendered":"\n<p>China&#8217;s Sciwind Biosciences Co., Ltd has entered into a licensing and partnership agreement with South Korea&#8217;s HK inno.N Corporation (<a href=\"https:\/\/www.google.com\/finance\/quote\/195940:KOSDAQ\">KOSDAQ: 195940<\/a>) for the development and commercialization of ecnoglutide injection (XW003), a novel glucagon-like peptide-1 (GLP-1) analog, for the treatment of type 2 diabetes, obesity, and metabolic associated severe hyperglycemia (MASH) in South Korea.<\/p>\n\n\n\n<p>Per the agreement&#8217;s terms, Sciwind Biosciences is set to receive an upfront payment and is eligible for additional development, regulatory, and commercial milestones of up to USD 56 million, plus double-digit royalties on future product sales. HK inno.N Corporation secures exclusive rights to develop and market ecnoglutide in South Korea, while Sciwind retains global rights for development and commercialization outside of South Korea.<\/p>\n\n\n\n<p>GLP-1 analogs are recognized as effective treatments for managing type 2 diabetes and obesity and show clinical potential for treating MASH. Ecnoglutide (XW003) is a novel, long-acting GLP-1 analog designed for improved biological activity, cost-effective production, and once-weekly dosing. It has shown benefits in treating patients with type 2 diabetes and obesity and has been found safe and well-tolerated in clinical trials.<\/p>\n\n\n\n<p>HK inno.N Corporation, initially the pharmaceutical division of CJ Cheil Jedang Corp., founded in 1984, was later acquired by Kolmar Korea Corp. in 2018. The company rebranded to HK inno.N Corp. in 2020, focusing on marketing prescription drugs, health foods, and cosmetics.- <a href=\"https:\/\/flcube.com\">Flcube.com<\/a><\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>China&#8217;s Sciwind Biosciences Co., Ltd has entered into a licensing and partnership agreement with South&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[39,2332,1554,86,822],"class_list":["post-3968","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-diabetes","tag-hk-inno-n","tag-kosdaq-195940","tag-obesity","tag-sciwind-biosciences"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>China\u2019s Sciwind Biosciences Partners with HK inno.N for Ecnoglutide Rights in South Korea - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China&#039;s Sciwind Biosciences Co., Ltd has entered into a licensing and partnership agreement with South Korea&#039;s HK inno.N Corporation (KOSDAQ: 195940) for the development and commercialization of ecnoglutide injection (XW003), a novel glucagon-like peptide-1 (GLP-1) analog, for the treatment of type 2 diabetes, obesity, and metabolic associated severe hyperglycemia (MASH) in South Korea.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=3968\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"China\u2019s Sciwind Biosciences Partners with HK inno.N for Ecnoglutide Rights in South Korea\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=3968\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2024-05-08T02:02:06+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-11-25T04:37:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=3968#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=3968\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"China\u2019s Sciwind Biosciences Partners with HK inno.N for Ecnoglutide Rights in South Korea\",\"datePublished\":\"2024-05-08T02:02:06+00:00\",\"dateModified\":\"2024-11-25T04:37:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=3968\"},\"wordCount\":237,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Diabetes\",\"HK inno.N\",\"KOSDAQ: 195940\",\"Obesity\",\"Sciwind Biosciences\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=3968#respond\"]}],\"copyrightYear\":\"2024\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=3968\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=3968\",\"name\":\"China\u2019s Sciwind Biosciences Partners with HK inno.N for Ecnoglutide Rights in South Korea - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2024-05-08T02:02:06+00:00\",\"dateModified\":\"2024-11-25T04:37:13+00:00\",\"description\":\"China's Sciwind Biosciences Co., Ltd has entered into a licensing and partnership agreement with South Korea's HK inno.N Corporation (KOSDAQ: 195940) for the development and commercialization of ecnoglutide injection (XW003), a novel glucagon-like peptide-1 (GLP-1) analog, for the treatment of type 2 diabetes, obesity, and metabolic associated severe hyperglycemia (MASH) in South Korea.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=3968#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=3968\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=3968#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"China\u2019s Sciwind Biosciences Partners with HK inno.N for Ecnoglutide Rights in South Korea\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"China\u2019s Sciwind Biosciences Partners with HK inno.N for Ecnoglutide Rights in South Korea - Insight, China&#039;s Pharmaceutical Industry","description":"China's Sciwind Biosciences Co., Ltd has entered into a licensing and partnership agreement with South Korea's HK inno.N Corporation (KOSDAQ: 195940) for the development and commercialization of ecnoglutide injection (XW003), a novel glucagon-like peptide-1 (GLP-1) analog, for the treatment of type 2 diabetes, obesity, and metabolic associated severe hyperglycemia (MASH) in South Korea.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=3968","og_locale":"en_US","og_type":"article","og_title":"China\u2019s Sciwind Biosciences Partners with HK inno.N for Ecnoglutide Rights in South Korea","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=3968","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2024-05-08T02:02:06+00:00","article_modified_time":"2024-11-25T04:37:13+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=3968#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=3968"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"China\u2019s Sciwind Biosciences Partners with HK inno.N for Ecnoglutide Rights in South Korea","datePublished":"2024-05-08T02:02:06+00:00","dateModified":"2024-11-25T04:37:13+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=3968"},"wordCount":237,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Diabetes","HK inno.N","KOSDAQ: 195940","Obesity","Sciwind Biosciences"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=3968#respond"]}],"copyrightYear":"2024","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=3968","url":"https:\/\/flcube.com\/?p=3968","name":"China\u2019s Sciwind Biosciences Partners with HK inno.N for Ecnoglutide Rights in South Korea - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2024-05-08T02:02:06+00:00","dateModified":"2024-11-25T04:37:13+00:00","description":"China's Sciwind Biosciences Co., Ltd has entered into a licensing and partnership agreement with South Korea's HK inno.N Corporation (KOSDAQ: 195940) for the development and commercialization of ecnoglutide injection (XW003), a novel glucagon-like peptide-1 (GLP-1) analog, for the treatment of type 2 diabetes, obesity, and metabolic associated severe hyperglycemia (MASH) in South Korea.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=3968#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=3968"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=3968#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"China\u2019s Sciwind Biosciences Partners with HK inno.N for Ecnoglutide Rights in South Korea"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/3968","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3968"}],"version-history":[{"count":2,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/3968\/revisions"}],"predecessor-version":[{"id":8989,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/3968\/revisions\/8989"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3968"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3968"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3968"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}